SAN DIEGO, Feb. 3, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Stemline Therapeutics, Inc. (NASDAQ: STML) violated state or federal laws.
On February 2, 2017, Bloomberg reported that a patient in a clinical trial of the Company's cancer drug SL-401 died from a severe side effect, this was the third death linked to the same SL-401 toxicity.
On this news, the Company's stock fell 42%, on February 2, 2017.
If you are a Stemline shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) at 619-814-4471. If you email, please include your phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stemline-stml-alert-shareholder-rights-law-firm-johnson--weaver-llp-investigates-stemline-therapeutics-inc-encourages-investors-to-contact-the-firm-for-additional-information-300401891.html
SOURCE Johnson & Weaver, LLP